{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:17:54Z","timestamp":1790882274063,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eimc.2020.02.018","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T08:26:01Z","timestamp":1585383961000},"page":"78-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efectos adversos neuropsiqui\u00e1tricos de dolutegravir en la pr\u00e1ctica cl\u00ednica real"],"prefix":"10.1016","volume":"39","author":[{"given":"Marina","family":"Povar-Echeverr\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Comet-Bernad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gasso-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Ger-Buil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herminia","family":"Navarro-Aznarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Mart\u00ednez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piedad","family":"Arazo-Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2020.02.018_bib0130","unstructured":"Grupo de Estudio del SIDA-SEIMC (GeSIDA). Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2018). 2018;1-141. Disponible en: http:\/\/gesida-seimc.org\/wp-content\/uploads\/2018\/01\/gesida_TAR_adultos_v3-1.pdf"},{"key":"10.1016\/j.eimc.2020.02.018_bib0135","unstructured":"European AIDS Clinical Society. Gu\u00eda Cl\u00ednica Tratamiento VIH 2017. 2017. Disponible en: https:\/\/www.eacsociety.org\/files\/guidlines-9.0-spanish.pdf"},{"key":"10.1016\/j.eimc.2020.02.018_bib0140","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimc.2020.02.018_bib0145","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV."},{"key":"10.1016\/j.eimc.2020.02.018_bib0150","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","volume":"4","author":"Orrell","year":"2017","journal-title":"Lancet HIV."},{"key":"10.1016\/j.eimc.2020.02.018_bib0155","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: A systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV."},{"key":"10.1016\/j.eimc.2020.02.018_bib0160","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/cid\/ciu477","article-title":"ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects","volume":"59","author":"Letendre","year":"2014","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.eimc.2020.02.018_bib0255","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.eimc.2020.02.018_bib0165","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.eimc.2020.02.018_bib0180","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase iii VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis."},{"key":"10.1016\/j.eimc.2020.02.018_bib0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0000000000001351","article-title":"Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir","volume":"31","author":"Bonfanti","year":"2017","journal-title":"AIDS."},{"key":"10.1016\/j.eimc.2020.02.018_bib0190","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/QAD.0000000000001459","article-title":"Neuropsychiatric adverse effects on dolutegravir","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS."},{"key":"10.1016\/j.eimc.2020.02.018_bib0195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0000000000001357","article-title":"Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients","volume":"31","author":"Borghetti","year":"2017","journal-title":"AIDS."},{"key":"10.1016\/j.eimc.2020.02.018_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med."},{"key":"10.1016\/j.eimc.2020.02.018_bib0205","unstructured":"Guido van den Berk G, Oryszczyn J, Blok W, van der Meche N, Regez R, Moha DA, et al. Unexpectedly high rate of intolerance for dolutegravir in real life setting. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Massachusetts, 22-25 February 2016."},{"key":"10.1016\/j.eimc.2020.02.018_bib0210","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1097\/QAD.0000000000001279","article-title":"Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice","volume":"30","author":"De Boer","year":"2016","journal-title":"AIDS."},{"key":"10.1016\/j.eimc.2020.02.018_bib0260","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bcpt.12828","article-title":"Clinical experience with the integrase inhibitors dolutegravir and elvitegravir in HIV-infected patients: Efficacy safety and tolerance","volume":"121","author":"Cid-Silva","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.eimc.2020.02.018_bib0215","unstructured":"P\u00e9rez Molina JA, Polo R, Mart\u00ednez E, coordinadores. Documento de Consenso de GeSIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualizaci\u00f3n enero 2015. Panel de expertos de GeSIDA y Plan Nacional sobre el SIDA; 2015. [consultado Jul 2019]. Disponible en: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/publicaciones\/profSanitarios\/RecomendacionesGesida_PNS26Enero2015.pdf"},{"key":"10.1016\/j.eimc.2020.02.018_bib0265","unstructured":"Vivancos-Gallego M, Moreno A, Perez-Elias M, Gomez Ayerbe C, Casado J, Quereda C, et al. Discontinuation of dolutegravir (DTG)-based regimens in clinical practice. HIV Drug Therapy. Glasgow, UK, 23-26 October 2016."},{"key":"10.1016\/j.eimc.2020.02.018_bib0230","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","article-title":"Adverse events of raltegravir and dolutegravir","volume":"31","author":"Elzi","year":"2017","journal-title":"AIDS."},{"key":"10.1016\/j.eimc.2020.02.018_bib0270","unstructured":"Llibre JM, Esteve A, Miro JM, Mateo G, Curran A, Podzamczer D, et al. Discontinuation of DTG, EVG\/c, and RAL due to toxicity in a prospective cohort. 24th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA, 13-16 February, 2017."},{"key":"10.1016\/j.eimc.2020.02.018_bib0235","doi-asserted-by":"crossref","unstructured":"Kheloufi F, Allemand J, Mokhtari S, Default A. Psychiatric disorders after starting dolutegravir: report of four cases. AIDS. 2015;29(13):1723-5. doi: 10.1097\/QAD.0000000000000789.","DOI":"10.1097\/QAD.0000000000000789"},{"key":"10.1016\/j.eimc.2020.02.018_bib0240","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jac\/dky497","article-title":"Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort","volume":"74","author":"Cuzin","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.eimc.2020.02.018_bib0250","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/2042098618798350","article-title":"Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database","volume":"9","author":"Hsu","year":"2018","journal-title":"Ther Adv Drug Saf [Internet]."}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:06:06Z","timestamp":1759323966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20300525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0213005X20300525"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2020.02.018","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos adversos neuropsiqui\u00e1tricos de dolutegravir en la pr\u00e1ctica cl\u00ednica real","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2020.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}